PBT-3, a hepoxilin stable analog, causes long term inhibition of growth of K562 solid tumours in vivo

We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumours derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumours in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2005-12, Vol.338 (1), p.158-160
Main Authors: Li, Xiang, Qiao, Na, Reynaud, Denis, Abdelhaleem, Mohamed, Pace-Asciak, Cecil R.
Format: Article
Language:English
Subjects:
8,11,14-Eicosatrienoic Acid - analogs & derivatives
8,11,14-Eicosatrienoic Acid - metabolism
8,11,14-Eicosatrienoic Acid - pharmacology
Animals
Antineoplastic Agents - metabolism
Antineoplastic Agents - pharmacology
Apoptosis
Biological Availability
Dose-Response Relationship, Drug
Female
Growth Inhibitors - metabolism
Growth Inhibitors - pharmacology
Hepoxilin stable analogs
Humans
K562
K562 Cells
Leukemia, Erythroblastic, Acute - drug therapy
Leukemia, Erythroblastic, Acute - metabolism
Mice
Mice, Nude
Neoplasm Transplantation
Novel therapeutics
NU/NU mice
PBT
Solid tumours
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumours derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumours in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumour growth is re-established. Similar findings were observed when the mice were treated with Gleevec (STI-571). These results provide new evidence that PBT-3 is effective in controlling solid tumour growth in vivo and suggest that the PBT family may be useful in the development of new drugs in cancer therapy.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2005.07.180